Literature DB >> 11263931

Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance.

A Ayhan1, E C Tok, I Bildirici, A Ayhan1.   

Abstract

OBJECTIVE: We evaluated the prognostic significance of CD44 isoform CD44 V6 in endometrial cancer.
METHOD: Immunohistochemistry was used to determine the expression of CD44 V6 in 78 randomly selected endometrial cancer specimens.
RESULTS: CD44 V6 was detected in 53% (41/78) of the tumor samples. Clinicopathological evaluation revealed an inverse correlation with CD44 V6 expression and conventional poor prognosticators such as lower segment involvement, nuclear and structural grade, myometrial invasion, serosal involvement, lymph-vascular space invasion, and adnexal metastasis. Furthermore, the CD44 V6-negative group was found to be associated have a higher recurrence rate and a shorter disease-free survival.
CONCLUSION: These findings indicate that absence of CD44 V6 expression in cases of endometrial cancer might be coupled with a more aggressive course. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11263931     DOI: 10.1006/gyno.2000.6014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial.

Authors:  Meenakshi Singh; Kathleen M Darcy; William E Brady; Rashna Clubwala; Zachary Weber; Jon V Rittenbach; Ali Akalin; Charles W Whitney; Richard Zaino; Nilsa C Ramirez; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2011-08-03       Impact factor: 5.482

Review 2.  Hyaluronan-CD44 interactions as potential targets for cancer therapy.

Authors:  Suniti Misra; Paraskevi Heldin; Vincent C Hascall; Nikos K Karamanos; Spyros S Skandalis; Roger R Markwald; Shibnath Ghatak
Journal:  FEBS J       Date:  2011-03-25       Impact factor: 5.542

3.  Impact of structurally modifying hyaluronic acid on CD44 interaction.

Authors:  D Bhattacharya; D Svechkarev; J J Souchek; T K Hill; M A Taylor; A Natarajan; A M Mohs
Journal:  J Mater Chem B       Date:  2017-09-20       Impact factor: 6.331

Review 4.  Metastasis review: from bench to bedside.

Authors:  Ali Mohammad Alizadeh; Sadaf Shiri; Sadaf Farsinejad
Journal:  Tumour Biol       Date:  2014-08-08

5.  Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE.

Authors:  Suniti Misra; Vincent C Hascall; Carla De Giovanni; Roger R Markwald; Shibnath Ghatak
Journal:  J Biol Chem       Date:  2009-02-26       Impact factor: 5.157

6.  Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma.

Authors:  Banu Dogan Gun; Burak Bahadir; Sibel Bektas; Figen Barut; Gamze Yurdakan; Nilufer Onak Kandemir; Sukru Oguz Ozdamar
Journal:  Diagn Pathol       Date:  2012-07-11       Impact factor: 2.644

7.  CD44 expression in curettage and postoperative specimens of endometrial cancer.

Authors:  Michał Wojciechowski; Tomasz Krawczyk; Janusz Śmigielski; Andrzej Malinowski
Journal:  Arch Gynecol Obstet       Date:  2014-08-17       Impact factor: 2.344

8.  EMP2 is a novel therapeutic target for endometrial cancer stem cells.

Authors:  M H Kiyohara; C Dillard; J Tsui; S R Kim; J Lu; D Sachdev; L Goodglick; M Tong; V F Torous; C Aryasomayajula; W Wang; P Najafzadeh; L K Gordon; J Braun; S McDermott; M S Wicha; M Wadehra
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 8.756

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.